Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

This fund can be held in an Investment ISA, SIPP and Investment Account The sub-fund has two aims: 1. to generate income and preserve capital with the potential for capital growth over any five-year ...

Graviss Hospitality Ltd., incorporated in the year 1959, is a Small Cap company (having a market cap of Rs 317.34 Crore) operating in Tourism & Hospitality sector. Graviss Hospitality Ltd. key ...